Cargando…
Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma
BACKGROUND: Glioblastoma (GBM) is a very frequent primary tumour in the cerebrospinal nervous system. Temozolomide (TMZ) is the first-line treatment for patients with GBM. However, some of GBM patients do not respond to TMZ. O6-methylguanine-DNA-methytransferase (MGMT) remains a major cause. In a pr...
Autores principales: | Wu, Yue, Zhang, Kai, Wang, Hao, Chen, Guangliang, Liu, Yongsheng, Li, Wen, Zhou, Youxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672402/ https://www.ncbi.nlm.nih.gov/pubmed/36407484 http://dx.doi.org/10.1016/j.bbrep.2022.101386 |
Ejemplares similares
-
A novel series of phenolic temozolomide (TMZ) esters with 4 to 5-fold increased potency, compared to TMZ, against glioma cells irrespective of MGMT expression
por: Shervington, Leroy, et al.
Publicado: (2020) -
Interstitial Control-Released Polymer Carrying a Targeting Small-Molecule Drug Reduces PD-L1 and MGMT Expression in Recurrent High-Grade Gliomas with TMZ Resistance
por: Liu, Ching-Ann, et al.
Publicado: (2022) -
Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021) -
Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma
por: Gonzalez-Aponte, Maria F., et al.
Publicado: (2023) -
Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation
por: Napoleoni, Luca, et al.
Publicado: (2019)